First Long-Term Rapamycin Trial Shows Safety and Modest Benefits for Healthy Aging
48-week study finds low-dose rapamycin safe with improvements in muscle mass and pain for women, but no major changes in body fat.
Summary
The PEARL trial, the longest clinical study of rapamycin for healthy aging to date, followed 114 adults for 48 weeks taking either placebo, 5mg, or 10mg rapamycin weekly. The study found that low-dose rapamycin was generally safe with similar adverse events across all groups. Women taking 10mg rapamycin showed significant improvements in lean muscle mass and reduced pain, while those on 5mg reported better emotional well-being and general health. However, the primary outcome of reducing visceral fat showed no significant changes. The compounded rapamycin used had only one-third the bioavailability of commercial formulations, potentially limiting effects.
Detailed Summary
Rapamycin, an FDA-approved drug that inhibits cellular aging pathways, has shown remarkable life-extending effects in laboratory animals but lacked long-term human safety and efficacy data for healthy aging applications.
The PEARL trial represents the first extended clinical study of rapamycin for longevity, following 114 healthy adults aged 50-85 for 48 weeks. Participants received either placebo, 5mg, or 10mg of compounded rapamycin weekly while researchers monitored safety and measured body composition changes using DXA scans, blood biomarkers, and quality of life surveys.
The study found rapamycin to be relatively safe, with adverse events similar across all groups, though gastrointestinal symptoms were slightly more common in rapamycin users. The primary endpoint of reducing visceral adipose tissue showed no significant changes. However, women taking 10mg rapamycin experienced meaningful improvements in lean tissue mass and reduced pain scores. Those on 5mg reported better emotional well-being and general health perceptions.
These modest but encouraging results suggest rapamycin may offer some healthspan benefits, particularly for women. However, the study used compounded rapamycin with only one-third the bioavailability of commercial formulations, potentially limiting the observed effects. The findings support rapamycin's safety profile at low intermittent doses while highlighting the need for larger studies with optimized formulations to fully evaluate its potential as a longevity intervention.
Key Findings
- Low-dose weekly rapamycin was safe with similar adverse events to placebo over 48 weeks
- Women taking 10mg rapamycin showed significant improvements in lean muscle mass
- Pain scores improved significantly in women on the higher rapamycin dose
- No significant changes observed in primary endpoint of visceral fat reduction
- Compounded rapamycin had reduced bioavailability compared to commercial formulations
Methodology
This was a 48-week randomized, double-blind, placebo-controlled trial with 114 participants receiving weekly doses of placebo, 5mg, or 10mg compounded rapamycin. Body composition was measured via DXA scans and safety monitored through adverse event reporting and blood biomarkers.
Study Limitations
The compounded rapamycin had significantly reduced bioavailability compared to commercial formulations, potentially limiting therapeutic effects. The study had relatively low female enrollment and modest sample sizes, requiring larger trials to confirm efficacy findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.